S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   382.60 (-1.87%)
AAPL   161.43 (-1.42%)
MSFT   322.73 (-2.05%)
FB   306.84 (-1.14%)
GOOGL   2,836.45 (-0.80%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.44 (+1.69%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   382.60 (-1.87%)
AAPL   161.43 (-1.42%)
MSFT   322.73 (-2.05%)
FB   306.84 (-1.14%)
GOOGL   2,836.45 (-0.80%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.44 (+1.69%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   382.60 (-1.87%)
AAPL   161.43 (-1.42%)
MSFT   322.73 (-2.05%)
FB   306.84 (-1.14%)
GOOGL   2,836.45 (-0.80%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.44 (+1.69%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   382.60 (-1.87%)
AAPL   161.43 (-1.42%)
MSFT   322.73 (-2.05%)
FB   306.84 (-1.14%)
GOOGL   2,836.45 (-0.80%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.44 (+1.69%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
NASDAQ:AVAH

Aveanna Healthcare Stock Competitors

$6.28
-0.04 (-0.63%)
(As of 12/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.07
$6.61
50-Day Range
$6.08
$8.84
52-Week Range
$5.97
$13.00
Volume
303,543 shs
Average Volume
640,303 shs
Market Capitalization
$1.16 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A

Aveanna Healthcare (NASDAQ:AVAH) Vs. FATE, PINC, HALO, HQY, PACB, CERE, AMED, OPCH, KOD, and INMD

Should you be buying Aveanna Healthcare stock or one of its competitors? The main competitors of Aveanna Healthcare include Fate Therapeutics (FATE), Premier (PINC), Halozyme Therapeutics (HALO), HealthEquity (HQY), Pacific Biosciences of California (PACB), Cerevel Therapeutics (CERE), Amedisys (AMED), Option Care Health (OPCH), Kodiak Sciences (KOD), and InMode (INMD). These companies are all part of the "home health care services" industry.These companies are all part of the "home health care services" industry.These companies are all part of the "medical" sector.

Aveanna Healthcare vs.

Aveanna Healthcare (NASDAQ:AVAH) and Premier (NASDAQ:PINC) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

68.1% of Aveanna Healthcare shares are held by institutional investors. Comparatively, 66.6% of Premier shares are held by institutional investors. 1.0% of Premier shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Aveanna Healthcare presently has a consensus price target of $13.75, indicating a potential upside of 118.95%. Premier has a consensus price target of $40.45, indicating a potential upside of 7.82%. Given Aveanna Healthcare's stronger consensus rating and higher possible upside, equities analysts clearly believe Aveanna Healthcare is more favorable than Premier.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aveanna Healthcare
0 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
3.00
Premier
3 Sell rating(s)
4 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.17

In the previous week, Premier had 5 more articles in the media than Aveanna Healthcare. MarketBeat recorded 12 mentions for Premier and 7 mentions for Aveanna Healthcare. Premier's average media sentiment score of 0.16 beat Aveanna Healthcare's score of 0.10 indicating that Premier is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aveanna Healthcare
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Premier
2 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral

Premier has a net margin of 15.17% compared to Aveanna Healthcare's net margin of 0.00%. Premier's return on equity of 12.64% beat Aveanna Healthcare's return on equity.

Company Net Margins Return on Equity Return on Assets
Aveanna Healthcare N/A N/A N/A
Premier 15.17% 12.64% 7.92%

Premier has higher revenue and earnings than Aveanna Healthcare.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aveanna HealthcareN/AN/AN/AN/AN/A
Premier$1.72 billion2.66$287.52 million$2.1217.70

Premier received 551 more outperform votes than Aveanna Healthcare when rated by MarketBeat users. However, 82.61% of users gave Aveanna Healthcare an outperform vote while only 70.46% of users gave Premier an outperform vote.

CompanyUnderperformOutperform
Aveanna HealthcareOutperform Votes
19
82.61%
Underperform Votes
4
17.39%
PremierOutperform Votes
570
70.46%
Underperform Votes
239
29.54%

Summary

Premier beats Aveanna Healthcare on 8 of the 14 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVAH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

Aveanna Healthcare (NASDAQ:AVAH) vs. Its Competitors

TypeAveanna HealthcareHome health care services IndustryMedical SectorNASDAQ Exchange
Market Cap$1.16B$3.15B$4.78B$7.64B
Dividend YieldN/A0.31%2.10%2.84%
P/E RatioN/A16.2222.4122.10
Price / SalesN/A2.242,457.19254.71
Price / CashN/A27.3440.47137.79
Price / BookN/A4.119.1610.02
Net IncomeN/A$75.86M$95.98M$154.20M
7 Day Performance-12.04%-6.04%-5.62%-5.37%
1 Month Performance-25.06%-17.98%-14.89%-11.86%
1 Year PerformanceN/A-15.25%9.65%23.59%

Aveanna Healthcare Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FATE
Fate Therapeutics
2.3281 of 5 stars
$47.94
-9.7%
$107.83
-124.9%
-13.1%$4.58B$31.43M-22.61279
PINC
Premier
2.3998 of 5 stars
$37.52
-1.3%
$40.45
-7.8%
+5.9%$4.57B$1.72B17.702,500Ex-Dividend
HALO
Halozyme Therapeutics
2.747 of 5 stars
$32.43
-2.3%
$53.00
-63.4%
-18.4%$4.57B$267.59M11.62136Analyst Report
News Coverage
HQY
HealthEquity
2.5257 of 5 stars
$54.35
-4.2%
$84.09
-54.7%
-20.6%$4.54B$733.57M5,435.003,039Upcoming Earnings
Analyst Report
PACB
Pacific Biosciences of California
2.1348 of 5 stars
$20.47
-5.3%
$50.00
-144.3%
+19.8%$4.52B$78.89M-97.48412
CERE
Cerevel Therapeutics
1.6531 of 5 stars
$30.63
-7.2%
$37.50
-22.4%
+118.3%$4.51BN/A-20.15122
AMED
Amedisys
2.5665 of 5 stars
$136.32
-3.9%
$203.71
-49.4%
-42.8%$4.44B$2.07B20.4721,000Insider Buying
OPCH
Option Care Health
2.5881 of 5 stars
$24.55
-3.2%
$27.14
-10.6%
+58.5%$4.42B$3.03B53.375,499Positive News
KOD
Kodiak Sciences
2.3065 of 5 stars
$84.06
-6.6%
$133.60
-58.9%
-31.4%$4.35BN/A-19.4172Gap Down
INMD
InMode
1.5 of 5 stars
$67.80
-6.2%
$81.00
-19.5%
+598.9%$4.34B$206.11M39.08311
PGNY
Progyny
2.6667 of 5 stars
$47.74
-2.7%
$68.00
-42.4%
+34.5%$4.32B$344.86M53.05210Analyst Report
ABCL
AbCellera Biologics
2.3667 of 5 stars
$15.29
-3.0%
$49.00
-220.5%
N/A$4.31B$233.15M0.00206
LIVN
LivaNova
2.4881 of 5 stars
$80.14
-2.7%
$103.50
-29.1%
+54.4%$4.27B$934.20M-9.644,000Analyst Report
Gap Up
NEOG
Neogen
1.7165 of 5 stars
$39.64
-2.0%
N/A+116.4%$4.26B$468.46M67.761,764
STAA
STAAR Surgical
2.2998 of 5 stars
$89.35
-3.1%
$150.00
-67.9%
+24.9%$4.25B$163.46M194.24575
AMEH
Apollo Medical
1.2431 of 5 stars
$75.53
-17.2%
$83.50
-10.6%
+396.0%$4.20B$687.18M47.50769News Coverage
High Trading Volume
ENSG
The Ensign Group
2.8981 of 5 stars
$75.61
-1.1%
$92.00
-21.7%
+8.9%$4.18B$2.40B22.3724,400Short Interest ↓
CERT
Certara
2.0586 of 5 stars
$26.10
-3.8%
$36.33
-39.2%
N/A$4.17B$243.53M-62.14300
OCDX
Ortho Clinical Diagnostics
2.3583 of 5 stars
$18.62
-3.1%
$26.00
-39.6%
N/A$4.14B$1.77B-37.244,500
TLRY
Tilray
1.8907 of 5 stars
$8.95
-6.6%
$14.35
-60.3%
+10.4%$4.12B$513.09M-4.642,100
CANO
Cano Health
2.3833 of 5 stars
$8.45
-10.2%
$17.50
-107.1%
N/A$4.06BN/A0.00N/AInsider Buying
IMAB
I-Mab
2.1583 of 5 stars
$52.69
-9.0%
$90.60
-71.9%
+54.7%$4.06B$236.42M0.002,020News Coverage
SGRY
Surgery Partners
2.1229 of 5 stars
$45.24
-1.9%
$53.14
-17.5%
+80.5%$4.04B$1.86B-33.769,950Analyst Report
TWST
Twist Bioscience
2.1448 of 5 stars
$81.14
-12.2%
$118.25
-45.7%
-20.9%$4.03B$90.10M-28.37525News Coverage
ALLK
Allakos
2.3431 of 5 stars
$74.01
-3.2%
$151.11
-104.2%
-21.6%$4.02BN/A-17.92125
EYE
National Vision
1.5775 of 5 stars
$48.00
-1.6%
$59.75
-24.5%
+14.4%$3.97B$1.71B27.1212,792Buyback Announcement
Gap Up
ARVN
Arvinas
2.2314 of 5 stars
$74.43
-2.7%
$128.44
-72.6%
+202.8%$3.94B$21.80M-19.59179Short Interest ↓
CGC
Canopy Growth
1.1874 of 5 stars
$9.99
-3.7%
$24.19
-142.2%
-63.2%$3.93B$414.03M-3.763,259Analyst Downgrade
NARI
Inari Medical
2.9083 of 5 stars
$77.71
-7.3%
$129.00
-66.0%
+28.4%$3.90B$139.67M287.83456Insider Selling
Short Interest ↓
CNMD
CONMED
2.575 of 5 stars
$131.78
-2.6%
$163.25
-23.9%
+35.7%$3.85B$862.46M65.893,400Dividend Announcement
SEM
Select Medical
2.9748 of 5 stars
$28.27
-0.9%
$42.75
-51.2%
+16.9%$3.79B$5.53B8.8942,350Short Interest ↓
NEO
NeoGenomics
2.5014 of 5 stars
$30.48
-6.1%
$54.89
-80.1%
-31.6%$3.75B$444.45M84.671,700
IONS
Ionis Pharmaceuticals
1.9181 of 5 stars
$26.39
-0.9%
$49.06
-85.9%
-49.0%$3.73B$729M-6.24757News Coverage
APLS
Apellis Pharmaceuticals
2.6371 of 5 stars
$41.70
-4.7%
$73.93
-77.3%
-3.9%$3.64B$250.65M-6.53374
ADPT
Adaptive Biotechnologies
1.9865 of 5 stars
$25.36
-3.4%
$60.33
-137.9%
-45.0%$3.58B$98.38M-18.51622News Coverage
MMSI
Merit Medical Systems
2.1664 of 5 stars
$63.33
-0.9%
$76.50
-20.8%
+14.3%$3.58B$963.88M83.335,989
ALKS
Alkermes
2.0931 of 5 stars
$22.09
-0.1%
$28.71
-30.0%
+17.5%$3.57B$1.04B-38.092,245Analyst Report
LHCG
LHC Group
2.1981 of 5 stars
$111.41
-3.1%
$177.60
-59.4%
-41.4%$3.53B$2.06B26.8530,000
KRTX
Karuna Therapeutics
2.3667 of 5 stars
$118.97
-6.4%
$166.82
-40.2%
+30.9%$3.52BN/A-24.3863Insider Selling
News Coverage
NVTA
Invitae
2.1673 of 5 stars
$14.99
-5.1%
$40.63
-171.0%
-68.1%$3.39B$279.60M-4.342,100
SKIN
Beauty Health
2.1583 of 5 stars
$22.35
-6.5%
$29.13
-30.3%
N/A$3.34BN/A0.002Short Interest ↓
ZNTL
Zentalis Pharmaceuticals
2.5333 of 5 stars
$72.70
-7.6%
$90.43
-24.4%
+53.0%$3.29BN/A-19.76124Insider Selling
SWTX
SpringWorks Therapeutics
2.5198 of 5 stars
$66.23
-7.0%
$117.50
-77.4%
+5.9%$3.26B$35M-30.2478
LFST
LifeStance Health Group
1.9153 of 5 stars
$8.67
-2.9%
$23.50
-171.0%
N/A$3.24B$265.56M0.002,674Lockup Expiration
Gap Down
High Trading Volume
SANA
Sana Biotechnology
1.5699 of 5 stars
$16.67
-10.2%
$38.50
-131.0%
N/A$3.15BN/A-1.79265
ME
23andMe
1.8167 of 5 stars
$7.66
-4.4%
$13.50
-76.2%
N/A$3.12BN/A0.00572
RCUS
Arcus Biosciences
2.4048 of 5 stars
$44.12
-2.0%
$64.25
-45.6%
+65.6%$3.10B$77.52M-10.76236
GLPG
Galapagos
1.5231 of 5 stars
$47.09
-2.5%
$98.26
-108.7%
-61.3%$3.09B$605.66M0.001,304Short Interest ↑
INSM
Insmed
2.0381 of 5 stars
$25.92
-4.0%
$55.17
-112.8%
-32.2%$3.07B$164.41M-6.61373
OMI
Owens & Minor
2.4265 of 5 stars
$40.51
-0.6%
$40.50
-0.0%
+60.1%$3.06B$8.48B12.8618,800Analyst Upgrade
This page was last updated on 12/3/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.